We advise you to exercise VanEck Vectors fundamental analysis to see if markets are presently mispricing the entity. In other words you can harness it to find out if VanEck Vectors Biotech is indeed mispriced or if you can make any profits on it by purchasing it and then waiting for the market to recognize its mistake and reprise the security. . We found eleven available drivers for VanEck Vectors Biotech ETF which can be compared to its competition. Please use VanEck Vectors One Year Return and Net Asset to make a decision on weather VanEck Vectors Biotech is priced fairly. Use VanEck Vectors to protect against small markets fluctuations. The etf experiences normal downward trend and little activity. Check odds of VanEck Vectors to be traded at $127.31 in 30 days
VanEck Vectors Company SummaryVanEck Vectors competes with Health Care, iShares Nasdaq, Vanguard Health, SPDR SP, and ISHARE DJ. The investment seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS US Listed Biotech 25 Index. The fund normally invests at least 80 percent of its total assets in securities that comprise the fund benchmark index. The Biotech Index includes common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology sector. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.
VanEck Vectors Net Asset vs Price to Earning
VanEck Vectors Biotech ETF is rated below average in net asset as compared to similar ETFs. It is fourth largest ETF in price to earning as compared to similar ETFs . The ratio of Net Asset to Price to Earning for VanEck Vectors Biotech ETF is about 33,495,470